These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23874769)

  • 1. An apolipoprotein A-I mimetic peptide designed with a reductionist approach stimulates reverse cholesterol transport and reduces atherosclerosis in mice.
    Ditiatkovski M; D'Souza W; Kesani R; Chin-Dusting J; de Haan JB; Remaley A; Sviridov D
    PLoS One; 2013; 8(7):e68802. PubMed ID: 23874769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 5A apolipoprotein mimetic peptide promotes cholesterol efflux and reduces atherosclerosis in mice.
    Amar MJ; D'Souza W; Turner S; Demosky S; Sviridov D; Stonik J; Luchoomun J; Voogt J; Hellerstein M; Sviridov D; Remaley AT
    J Pharmacol Exp Ther; 2010 Aug; 334(2):634-41. PubMed ID: 20484557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of native and myeloperoxidase-modified apolipoprotein a-I on reverse cholesterol transport and atherosclerosis in mice.
    Hewing B; Parathath S; Barrett T; Chung WK; Astudillo YM; Hamada T; Ramkhelawon B; Tallant TC; Yusufishaq MS; Didonato JA; Huang Y; Buffa J; Berisha SZ; Smith JD; Hazen SL; Fisher EA
    Arterioscler Thromb Vasc Biol; 2014 Apr; 34(4):779-89. PubMed ID: 24407029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein A-I Mimetic Peptides: Discordance Between In Vitro and In Vivo Properties-Brief Report.
    Ditiatkovski M; Palsson J; Chin-Dusting J; Remaley AT; Sviridov D
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1301-1306. PubMed ID: 28522696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice.
    Bielicki JK; Zhang H; Cortez Y; Zheng Y; Narayanaswami V; Patel A; Johansson J; Azhar S
    J Lipid Res; 2010 Jun; 51(6):1496-503. PubMed ID: 20075422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice.
    Navab M; Anantharamaiah GM; Reddy ST; Hama S; Hough G; Grijalva VR; Wagner AC; Frank JS; Datta G; Garber D; Fogelman AM
    Circulation; 2004 Jun; 109(25):3215-20. PubMed ID: 15197147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CER-001, a HDL-mimetic, stimulates the reverse lipid transport and atherosclerosis regression in high cholesterol diet-fed LDL-receptor deficient mice.
    Tardy C; Goffinet M; Boubekeur N; Ackermann R; Sy G; Bluteau A; Cholez G; Keyserling C; Lalwani N; Paolini JF; Dasseux JL; Barbaras R; Baron R
    Atherosclerosis; 2014 Jan; 232(1):110-8. PubMed ID: 24401224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoE-knockout mice fed high-fat diet.
    Song G; Liu J; Zhao Z; Yu Y; Tian H; Yao S; Li G; Qin S
    Lipids Health Dis; 2011 Jan; 10():8. PubMed ID: 21241519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function.
    Anantharamaiah GM; Garber DW; White CR
    Protein Pept Lett; 2016; 23(11):1024-1031. PubMed ID: 27586181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced atheroprotection and lesion remodelling by targeting the foam cell and increasing plasma cholesterol acceptors.
    Son SH; Goo YH; Choi M; Saha PK; Oka K; Chan LC; Paul A
    Cardiovasc Res; 2016 Feb; 109(2):294-304. PubMed ID: 26487692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reverse D4F, an apolipoprotein-AI mimetic peptide, inhibits atherosclerosis in ApoE-null mice.
    Qin S; Kamanna VS; Lai JH; Liu T; Ganji SH; Zhang L; Bachovchin WW; Kashyap ML
    J Cardiovasc Pharmacol Ther; 2012 Sep; 17(3):334-43. PubMed ID: 22308547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel apoA-I mimetic peptide suppresses atherosclerosis by promoting physiological HDL function in apoE
    Gou S; Wang L; Zhong C; Chen X; Ouyang X; Li B; Bao G; Liu H; Zhang Y; Ni J
    Br J Pharmacol; 2020 Oct; 177(20):4627-4644. PubMed ID: 32726461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis.
    Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B
    Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein A-I protection against atherosclerosis is dependent on genetic background.
    Sontag TJ; Krishack PA; Lukens JR; Bhanvadia CV; Getz GS; Reardon CA
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):262-9. PubMed ID: 24334873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure/function relationships of apolipoprotein a-I mimetic peptides: implications for antiatherogenic activities of high-density lipoprotein.
    D'Souza W; Stonik JA; Murphy A; Demosky SJ; Sethi AA; Moore XL; Chin-Dusting J; Remaley AT; Sviridov D
    Circ Res; 2010 Jul; 107(2):217-27. PubMed ID: 20508181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein A-I mimetic peptide helix number and helix linker influence potentially anti-atherogenic properties.
    Wool GD; Reardon CA; Getz GS
    J Lipid Res; 2008 Jun; 49(6):1268-83. PubMed ID: 18323574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase 8 degrades apolipoprotein A-I and reduces its cholesterol efflux capacity.
    Salminen A; Åström P; Metso J; Soliymani R; Salo T; Jauhiainen M; Pussinen PJ; Sorsa T
    FASEB J; 2015 Apr; 29(4):1435-45. PubMed ID: 25550459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The apolipoprotein-AI mimetic peptide L4F at a modest dose does not attenuate weight gain, inflammation, or atherosclerosis in LDLR-null mice.
    Averill MM; Kim EJ; Goodspeed L; Wang S; Subramanian S; Den Hartigh LJ; Tang C; Ding Y; Reardon CA; Getz GS; Chait A
    PLoS One; 2014; 9(10):e109252. PubMed ID: 25286043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein mimetic peptides: Mechanisms of action as anti-atherogenic agents.
    Osei-Hwedieh DO; Amar M; Sviridov D; Remaley AT
    Pharmacol Ther; 2011 Apr; 130(1):83-91. PubMed ID: 21172387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein A-I mimetic peptides prevent atherosclerosis development and reduce plaque inflammation in a murine model of diabetes.
    Morgantini C; Imaizumi S; Grijalva V; Navab M; Fogelman AM; Reddy ST
    Diabetes; 2010 Dec; 59(12):3223-8. PubMed ID: 20826564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.